BERGEN, Norway, December 8, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that Martin Olin, Chief Executive Officer of BerGenBio, will present at the 13th Annual DNB Nordic Healthcare Conference in Oslo, Norway, on Thursday, December 15, 2022, at 11:45am … Read more
Bergen, Norway, 21 November 2022 – BerGenBio ASA (the “Company”) (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announce that the Board of Directors has granted options to employees. The annual general meeting in the Company 28 April 2022 approved the share option program and authorised … Read more
– Randomized first patient in the Phase 2b EU-SolidAct platform for hospitalized COVID-19 patients – – Initiated Phase 1b/2a trial in 1st line NSCLC patients harboring STK11 mutations – – Strengthened financial position with support from largest shareholder – BERGEN, Norway, November 15, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, … Read more
Bergen, Norway, 8 November 2022- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will be announcing its results for the third quarter 2022 on Tuesday 15 November 2022. The briefing will take place at 10:00 am CET at: Carnegie AS, Fjordalleen 16, Aker Brygge, 5th Floor, … Read more
BERGEN, Norway, October 25, 2022: BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, and Meteva AS, a 27.23% shareholder in BerGenBio, today announced that they have entered into a shareholder loan facility, pursuant to which Meteva will make available to BerGenBio up to NOK … Read more
– Study will assess bemcentinib in combination with current standard of care for 1st line NSCLC – – Approximately 20% of NSCLC patients have STK11 mutations – – First patient is expected to be dosed in 4Q22 – BERGEN, Norway, October 11, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective … Read more
BERGEN, Norway, September 27, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharma-ceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, and Oslo University Hospital announced today that the first patient has been included in a study of BerGenBio’s oral, highly selective AXL inhibitor, bemcentinib, as part of the EU-SolidAct trial … Read more
BERGEN, Norway, September 7, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that Martin Olin, Chief Executive Officer of BerGenBio, will present at Pareto Securities’ 13th Annual Healthcare Conference in Stockholm, Sweden, on Wednesday, September 7, 2022, at 8:15am CEST. … Read more
– Commenced bemcentinib Phase 2b trial in hospitalized COVID-19 patients – – Initiation of Phase 1a/2b STK11 mutated NSCLC trial planned for 2H22 – – BerGenBio to host conference call and webcast today at 10:00 AM CEST/4:00 AM EDT – BERGEN, Norway, August 23, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing … Read more
Bergen, Norway, 9 August 2022- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will be announcing its results for the second quarter and half year 2022 on Tuesday 23 August 2022. The briefing will take place at 10:00 am CET at: Carnegie AS, Fjordalleen 16, Aker … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.